Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
The G8 countries contributed $534.8 billion in 2011 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011.The G8 countries are expected to reach a value of $600.2 billion in 2016, with a CAGR of 2.3% over the 2011-16 period.
Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.
Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $262.7 billion in 2011.
The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $299.5 billion in 2016.
Why you should buy this report
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
Scope of the Report
- Contains an executive summary and data on value, volume and segmentation
- Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
- Incorporates in-depth five forces competitive environment analysis and scorecards
- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country.
- Includes a five-year forecast of the industry
The G8 countries contributed $534.8 billion in 2011 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011.The G8 countries are expected to reach a value of $600.2 billion in 2016, with a CAGR of 2.3% over the 2011-16 period.
Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.
Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $262.7 billion in 2011.
The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $299.5 billion in 2016.
Why you should buy this report
- Spot future trends and developments
- Inform your business decisions
- Add weight to presentations and marketing materials
- Save time carrying out entry-level research
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G8) Pharmaceuticals Industry Outlook
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
LIST OF TABLES
Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16
Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011
Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11
Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16
Table 5: Canada pharmaceuticals market value: $ billion, 2007–11
Table 6: Canada pharmaceuticals market geography segmentation: $ billion, 2011
Table 7: Canada pharmaceuticals market share: % share, by value, 2011
Table 8: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Table 9: Canada size of population (million), 2007–11
Table 10: Canada gdp (constant 2000 prices, $ billion), 2007–11
Table 11: Canada gdp (current prices, $ billion), 2007–11
Table 12: Canada inflation, 2007–11
Table 13: Canada consumer price index (absolute), 2007–11
Table 14: Canada exchange rate, 2007–11
Table 15: France pharmaceuticals market value: $ billion, 2007–11
Table 16: France pharmaceuticals market geography segmentation: $ billion, 2011
Table 17: France pharmaceuticals market share: % share, by value, 2011
Table 18: France pharmaceuticals market value forecast: $ billion, 2011–16
Table 19: France size of population (million), 2007–11
Table 20: France gdp (constant 2000 prices, $ billion), 2007–11
Table 21: France gdp (current prices, $ billion), 2007–11
Table 22: France inflation, 2007–11
Table 23: France consumer price index (absolute), 2007–11
Table 24: France exchange rate, 2007–11
Table 25: Germany pharmaceuticals market value: $ billion, 2007–11
Table 26: Germany pharmaceuticals market geography segmentation: $ billion, 2011
Table 27: Germany pharmaceuticals market share: % share, by value, 2011
Table 28: Germany pharmaceuticals market value forecast: $ billion, 2011–16
Table 29: Germany size of population (million), 2007–11
Table 30: Germany gdp (constant 2000 prices, $ billion), 2007–11
Table 31: Germany gdp (current prices, $ billion), 2007–11
Table 32: Germany inflation, 2007–11
Table 33: Germany consumer price index (absolute), 2007–11
Table 34: Germany exchange rate, 2007–11
Table 35: Italy pharmaceuticals market value: $ billion, 2007–11
Table 36: Italy pharmaceuticals market geography segmentation: $ billion, 2011
Table 37: Italy pharmaceuticals market share: % share, by value, 2011
Table 38: Italy pharmaceuticals market value forecast: $ billion, 2011–16
Table 39: Italy size of population (million), 2007–11
Table 40: Italy gdp (constant 2000 prices, $ billion), 2007–11
Table 41: Italy gdp (current prices, $ billion), 2007–11
Table 42: Italy inflation, 2007–11
Table 43: Italy consumer price index (absolute), 2007–11
Table 44: Italy exchange rate, 2007–11
Table 45: Japan pharmaceuticals market value: $ billion, 2007–11
Table 46: Japan pharmaceuticals market geography segmentation: $ billion, 2011
Table 47: Japan pharmaceuticals market share: % share, by value, 2011
Table 48: Japan pharmaceuticals market value forecast: $ billion, 2011–16
Table 49: Japan size of population (million), 2007–11
Table 50: Japan gdp (constant 2000 prices, $ billion), 2007–11
Table 51: Japan gdp (current prices, $ billion), 2007–11
Table 52: Japan inflation, 2007–11
Table 53: Japan consumer price index (absolute), 2007–11
Table 54: Japan exchange rate, 2007–11
Table 55: Russia pharmaceuticals market value: $ billion, 2007–11
Table 56: Russia pharmaceuticals market geography segmentation: $ billion, 2011
Table 57: Russia pharmaceuticals market share: % share, by value, 2011
Table 58: Russia pharmaceuticals market value forecast: $ billion, 2011–16
Table 59: Russia size of population (million), 2007–11
Table 60: Russia gdp (constant 2000 prices, $ billion), 2007–11
Table 61: Russia gdp (current prices, $ billion), 2007–11
Table 62: Russia inflation, 2007–11
Table 63: Russia consumer price index (absolute), 2007–11
Table 64: Russia exchange rate, 2007–11
Table 65: United Kingdom pharmaceuticals market value: $ billion, 2007–11
Table 66: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011
Table 67: United Kingdom pharmaceuticals market share: % share, by value, 2011
Table 68: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16
Table 69: United Kingdom size of population (million), 2007–11
Table 70: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11
Table 71: United Kingdom gdp (current prices, $ billion), 2007–11
Table 72: United Kingdom inflation, 2007–11
Table 73: United Kingdom consumer price index (absolute), 2007–11
Table 74: United Kingdom exchange rate, 2007–11
Table 75: United States pharmaceuticals market value: $ billion, 2007–11
Table 76: United States pharmaceuticals market geography segmentation: $ billion, 2011
Table 77: United States pharmaceuticals market share: % share, by value, 2011
Table 78: United States pharmaceuticals market value forecast: $ billion, 2011–16
Table 79: United States size of population (million), 2007–11
Table 80: United States gdp (constant 2000 prices, $ billion), 2007–11
Table 81: United States gdp (current prices, $ billion), 2007–11
Table 82: United States inflation, 2007–11
Table 83: United States consumer price index (absolute), 2007–11
Table 84: United States exchange rate, 2007–11
Table 85: Johnson & Johnson: key facts
Table 86: Johnson & Johnson: key financials ($)
Table 87: Johnson & Johnson: key financial ratios
Table 88: Pfizer Inc.: key facts
Table 89: Pfizer Inc.: key financials ($)
Table 90: Pfizer Inc.: key financial ratios
Table 91: AstraZeneca PLC: key facts
Table 92: AstraZeneca PLC: key financials ($)
Table 93: AstraZeneca PLC: key financial ratios
Table 94: GlaxoSmithKline Plc: key facts
Table 95: GlaxoSmithKline Plc: key financials ($)
Table 96: GlaxoSmithKline Plc: key financials (£)
Table 97: GlaxoSmithKline Plc: key financial ratios
Table 98: Novartis AG: key facts
Table 99: Novartis AG: key financials ($)
Table 100: Novartis AG: key financial ratios
Table 101: Chiesi Farmaceutici S.P.A.: key facts
Table 102: Menarini Group, The: key facts
Table 103: Takeda Pharmaceutical Company Limited: key facts
Table 104: Takeda Pharmaceutical Company Limited: key financials ($)
Table 105: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 106: Takeda Pharmaceutical Company Limited: key financial ratios
Table 107: Daiichi Sankyo Co., Ltd.: key facts
Table 108: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 109: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 111: Mitsubishi Tanabe Pharma Corporation: key facts
Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 113: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 115: Pharmstandard OJSC: key facts
Table 116: Pharmstandard OJSC: key financials ($)
Table 117: Pharmstandard OJSC: key financials (RUB)
Table 118: Pharmstandard OJSC: key financial ratios
Table 119: Sanofi: key facts
Table 120: Sanofi: key financials ($)
Table 121: Sanofi: key financials (€)
Table 122: Sanofi: key financial ratios
Table 123: Bayer AG: key facts
Table 124: Bayer AG: key financials ($)
Table 125: Bayer AG: key financials (€)
Table 126: Bayer AG: key financial ratios
Table 127: Merck & Co., Inc.: key facts
Table 128: Merck & Co., Inc.: key financials ($)
Table 129: Merck & Co., Inc.: key financial ratios
LIST OF FIGURES
Figure 1: G8 pharmaceuticals industry, revenue($bn), 2007-16
Figure 2: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11
Figure 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16
Figure 4: Canada pharmaceuticals market value: $ billion, 2007–11
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 6: Canada pharmaceuticals market share: % share, by value, 2011
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2011
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2011
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2011
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011
Figure 14: France pharmaceuticals market value: $ billion, 2007–11
Figure 15: France pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 16: France pharmaceuticals market share: % share, by value, 2011
Figure 17: France pharmaceuticals market value forecast: $ billion, 2011–16
Figure 18: Forces driving competition in the pharmaceuticals market in France, 2011
Figure 19: Drivers of buyer power in the pharmaceuticals market in France, 2011
Figure 20: Drivers of supplier power in the pharmaceuticals market in France, 2011
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011
Figure 24: Germany pharmaceuticals market value: $ billion, 2007–11
Figure 25: Germany pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 26: Germany pharmaceuticals market share: % share, by value, 2011
Figure 27: Germany pharmaceuticals market value forecast: $ billion, 2011–16
Figure 28: Forces driving competition in the pharmaceuticals market in Germany, 2011
Figure 29: Drivers of buyer power in the pharmaceuticals market in Germany, 2011
Figure 30: Drivers of supplier power in the pharmaceuticals market in Germany, 2011
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011
Figure 34: Italy pharmaceuticals market value: $ billion, 2007–11
Figure 35: Italy pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 36: Italy pharmaceuticals market share: % share, by value, 2011
Figure 37: Italy pharmaceuticals market value forecast: $ billion, 2011–16
Figure 38: Forces driving competition in the pharmaceuticals market in Italy, 2011
Figure 39: Drivers of buyer power in the pharmaceuticals market in Italy, 2011
Figure 40: Drivers of supplier power in the pharmaceuticals market in Italy, 2011
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011
Figure 44: Japan pharmaceuticals market value: $ billion, 2007–11
Figure 45: Japan pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 46: Japan pharmaceuticals market share: % share, by value, 2011
Figure 47: Japan pharmaceuticals market value forecast: $ billion, 2011–16
Figure 48: Forces driving competition in the pharmaceuticals market in Japan, 2011
Figure 49: Drivers of buyer power in the pharmaceuticals market in Japan, 2011
Figure 50: Drivers of supplier power in the pharmaceuticals market in Japan, 2011
Figure 51: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011
Figure 52: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011
Figure 53: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011
Figure 54: Russia pharmaceuticals market value: $ billion, 2007–11
Figure 55: Russia pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 56: Russia pharmaceuticals market share: % share, by value, 2011
Figure 57: Russia pharmaceuticals market value forecast: $ billion, 2011–16
Figure 58: Forces driving competition in the pharmaceuticals market in Russia, 2011
Figure 59: Drivers of buyer power in the pharmaceuticals market in Russia, 2011
Figure 60: Drivers of supplier power in the pharmaceuticals market in Russia, 2011
Figure 61: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011
Figure 62: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011
Figure 63: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011
Figure 64: United Kingdom pharmaceuticals market value: $ billion, 2007–11
Figure 65: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 66: United Kingdom pharmaceuticals market share: % share, by value, 2011
Figure 67: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16
Figure 68: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011
Figure 69: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011
Figure 70: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011
Figure 71: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011
Figure 72: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011
Figure 73: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011
Figure 74: United States pharmaceuticals market value: $ billion, 2007–11
Figure 75: United States pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 76: United States pharmaceuticals market share: % share, by value, 2011
Figure 77: United States pharmaceuticals market value forecast: $ billion, 2011–16
Figure 78: Forces driving competition in the pharmaceuticals market in the United States, 2011
Figure 79: Drivers of buyer power in the pharmaceuticals market in the United States, 2011
Figure 80: Drivers of supplier power in the pharmaceuticals market in the United States, 2011
Figure 81: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011
Figure 82: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011
Figure 83: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011
Figure 84: Johnson & Johnson: revenues & profitability
Figure 85: Johnson & Johnson: assets & liabilities
Figure 86: Pfizer Inc.: revenues & profitability
Figure 87: Pfizer Inc.: assets & liabilities
Figure 88: AstraZeneca PLC: revenues & profitability
Figure 89: AstraZeneca PLC: assets & liabilities
Figure 90: GlaxoSmithKline Plc: revenues & profitability
Figure 91: GlaxoSmithKline Plc: assets & liabilities
Figure 92: Novartis AG: revenues & profitability
Figure 93: Novartis AG: assets & liabilities
Figure 94: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 95: Takeda Pharmaceutical Company Limited: assets & liabilities
Figure 96: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 97: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 98: Mitsubishi Tanabe Pharma Corporation: revenues & profitability
Figure 99: Mitsubishi Tanabe Pharma Corporation: assets & liabilities
Figure 100: Pharmstandard OJSC: revenues & profitability
Figure 101: Pharmstandard OJSC: assets & liabilities
Figure 102: Sanofi: revenues & profitability
Figure 103: Sanofi: assets & liabilities
Figure 104: Bayer AG: revenues & profitability
Figure 105: Bayer AG: assets & liabilities
Figure 106: Merck & Co., Inc.: revenues & profitability
Figure 107: Merck & Co., Inc.: assets & liabilities
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G8) Pharmaceuticals Industry Outlook
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
LIST OF TABLES
Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16
Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011
Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11
Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16
Table 5: Canada pharmaceuticals market value: $ billion, 2007–11
Table 6: Canada pharmaceuticals market geography segmentation: $ billion, 2011
Table 7: Canada pharmaceuticals market share: % share, by value, 2011
Table 8: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Table 9: Canada size of population (million), 2007–11
Table 10: Canada gdp (constant 2000 prices, $ billion), 2007–11
Table 11: Canada gdp (current prices, $ billion), 2007–11
Table 12: Canada inflation, 2007–11
Table 13: Canada consumer price index (absolute), 2007–11
Table 14: Canada exchange rate, 2007–11
Table 15: France pharmaceuticals market value: $ billion, 2007–11
Table 16: France pharmaceuticals market geography segmentation: $ billion, 2011
Table 17: France pharmaceuticals market share: % share, by value, 2011
Table 18: France pharmaceuticals market value forecast: $ billion, 2011–16
Table 19: France size of population (million), 2007–11
Table 20: France gdp (constant 2000 prices, $ billion), 2007–11
Table 21: France gdp (current prices, $ billion), 2007–11
Table 22: France inflation, 2007–11
Table 23: France consumer price index (absolute), 2007–11
Table 24: France exchange rate, 2007–11
Table 25: Germany pharmaceuticals market value: $ billion, 2007–11
Table 26: Germany pharmaceuticals market geography segmentation: $ billion, 2011
Table 27: Germany pharmaceuticals market share: % share, by value, 2011
Table 28: Germany pharmaceuticals market value forecast: $ billion, 2011–16
Table 29: Germany size of population (million), 2007–11
Table 30: Germany gdp (constant 2000 prices, $ billion), 2007–11
Table 31: Germany gdp (current prices, $ billion), 2007–11
Table 32: Germany inflation, 2007–11
Table 33: Germany consumer price index (absolute), 2007–11
Table 34: Germany exchange rate, 2007–11
Table 35: Italy pharmaceuticals market value: $ billion, 2007–11
Table 36: Italy pharmaceuticals market geography segmentation: $ billion, 2011
Table 37: Italy pharmaceuticals market share: % share, by value, 2011
Table 38: Italy pharmaceuticals market value forecast: $ billion, 2011–16
Table 39: Italy size of population (million), 2007–11
Table 40: Italy gdp (constant 2000 prices, $ billion), 2007–11
Table 41: Italy gdp (current prices, $ billion), 2007–11
Table 42: Italy inflation, 2007–11
Table 43: Italy consumer price index (absolute), 2007–11
Table 44: Italy exchange rate, 2007–11
Table 45: Japan pharmaceuticals market value: $ billion, 2007–11
Table 46: Japan pharmaceuticals market geography segmentation: $ billion, 2011
Table 47: Japan pharmaceuticals market share: % share, by value, 2011
Table 48: Japan pharmaceuticals market value forecast: $ billion, 2011–16
Table 49: Japan size of population (million), 2007–11
Table 50: Japan gdp (constant 2000 prices, $ billion), 2007–11
Table 51: Japan gdp (current prices, $ billion), 2007–11
Table 52: Japan inflation, 2007–11
Table 53: Japan consumer price index (absolute), 2007–11
Table 54: Japan exchange rate, 2007–11
Table 55: Russia pharmaceuticals market value: $ billion, 2007–11
Table 56: Russia pharmaceuticals market geography segmentation: $ billion, 2011
Table 57: Russia pharmaceuticals market share: % share, by value, 2011
Table 58: Russia pharmaceuticals market value forecast: $ billion, 2011–16
Table 59: Russia size of population (million), 2007–11
Table 60: Russia gdp (constant 2000 prices, $ billion), 2007–11
Table 61: Russia gdp (current prices, $ billion), 2007–11
Table 62: Russia inflation, 2007–11
Table 63: Russia consumer price index (absolute), 2007–11
Table 64: Russia exchange rate, 2007–11
Table 65: United Kingdom pharmaceuticals market value: $ billion, 2007–11
Table 66: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011
Table 67: United Kingdom pharmaceuticals market share: % share, by value, 2011
Table 68: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16
Table 69: United Kingdom size of population (million), 2007–11
Table 70: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11
Table 71: United Kingdom gdp (current prices, $ billion), 2007–11
Table 72: United Kingdom inflation, 2007–11
Table 73: United Kingdom consumer price index (absolute), 2007–11
Table 74: United Kingdom exchange rate, 2007–11
Table 75: United States pharmaceuticals market value: $ billion, 2007–11
Table 76: United States pharmaceuticals market geography segmentation: $ billion, 2011
Table 77: United States pharmaceuticals market share: % share, by value, 2011
Table 78: United States pharmaceuticals market value forecast: $ billion, 2011–16
Table 79: United States size of population (million), 2007–11
Table 80: United States gdp (constant 2000 prices, $ billion), 2007–11
Table 81: United States gdp (current prices, $ billion), 2007–11
Table 82: United States inflation, 2007–11
Table 83: United States consumer price index (absolute), 2007–11
Table 84: United States exchange rate, 2007–11
Table 85: Johnson & Johnson: key facts
Table 86: Johnson & Johnson: key financials ($)
Table 87: Johnson & Johnson: key financial ratios
Table 88: Pfizer Inc.: key facts
Table 89: Pfizer Inc.: key financials ($)
Table 90: Pfizer Inc.: key financial ratios
Table 91: AstraZeneca PLC: key facts
Table 92: AstraZeneca PLC: key financials ($)
Table 93: AstraZeneca PLC: key financial ratios
Table 94: GlaxoSmithKline Plc: key facts
Table 95: GlaxoSmithKline Plc: key financials ($)
Table 96: GlaxoSmithKline Plc: key financials (£)
Table 97: GlaxoSmithKline Plc: key financial ratios
Table 98: Novartis AG: key facts
Table 99: Novartis AG: key financials ($)
Table 100: Novartis AG: key financial ratios
Table 101: Chiesi Farmaceutici S.P.A.: key facts
Table 102: Menarini Group, The: key facts
Table 103: Takeda Pharmaceutical Company Limited: key facts
Table 104: Takeda Pharmaceutical Company Limited: key financials ($)
Table 105: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 106: Takeda Pharmaceutical Company Limited: key financial ratios
Table 107: Daiichi Sankyo Co., Ltd.: key facts
Table 108: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 109: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 111: Mitsubishi Tanabe Pharma Corporation: key facts
Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 113: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 115: Pharmstandard OJSC: key facts
Table 116: Pharmstandard OJSC: key financials ($)
Table 117: Pharmstandard OJSC: key financials (RUB)
Table 118: Pharmstandard OJSC: key financial ratios
Table 119: Sanofi: key facts
Table 120: Sanofi: key financials ($)
Table 121: Sanofi: key financials (€)
Table 122: Sanofi: key financial ratios
Table 123: Bayer AG: key facts
Table 124: Bayer AG: key financials ($)
Table 125: Bayer AG: key financials (€)
Table 126: Bayer AG: key financial ratios
Table 127: Merck & Co., Inc.: key facts
Table 128: Merck & Co., Inc.: key financials ($)
Table 129: Merck & Co., Inc.: key financial ratios
LIST OF FIGURES
Figure 1: G8 pharmaceuticals industry, revenue($bn), 2007-16
Figure 2: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11
Figure 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16
Figure 4: Canada pharmaceuticals market value: $ billion, 2007–11
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 6: Canada pharmaceuticals market share: % share, by value, 2011
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2011
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2011
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2011
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011
Figure 14: France pharmaceuticals market value: $ billion, 2007–11
Figure 15: France pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 16: France pharmaceuticals market share: % share, by value, 2011
Figure 17: France pharmaceuticals market value forecast: $ billion, 2011–16
Figure 18: Forces driving competition in the pharmaceuticals market in France, 2011
Figure 19: Drivers of buyer power in the pharmaceuticals market in France, 2011
Figure 20: Drivers of supplier power in the pharmaceuticals market in France, 2011
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011
Figure 24: Germany pharmaceuticals market value: $ billion, 2007–11
Figure 25: Germany pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 26: Germany pharmaceuticals market share: % share, by value, 2011
Figure 27: Germany pharmaceuticals market value forecast: $ billion, 2011–16
Figure 28: Forces driving competition in the pharmaceuticals market in Germany, 2011
Figure 29: Drivers of buyer power in the pharmaceuticals market in Germany, 2011
Figure 30: Drivers of supplier power in the pharmaceuticals market in Germany, 2011
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011
Figure 34: Italy pharmaceuticals market value: $ billion, 2007–11
Figure 35: Italy pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 36: Italy pharmaceuticals market share: % share, by value, 2011
Figure 37: Italy pharmaceuticals market value forecast: $ billion, 2011–16
Figure 38: Forces driving competition in the pharmaceuticals market in Italy, 2011
Figure 39: Drivers of buyer power in the pharmaceuticals market in Italy, 2011
Figure 40: Drivers of supplier power in the pharmaceuticals market in Italy, 2011
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011
Figure 44: Japan pharmaceuticals market value: $ billion, 2007–11
Figure 45: Japan pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 46: Japan pharmaceuticals market share: % share, by value, 2011
Figure 47: Japan pharmaceuticals market value forecast: $ billion, 2011–16
Figure 48: Forces driving competition in the pharmaceuticals market in Japan, 2011
Figure 49: Drivers of buyer power in the pharmaceuticals market in Japan, 2011
Figure 50: Drivers of supplier power in the pharmaceuticals market in Japan, 2011
Figure 51: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011
Figure 52: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011
Figure 53: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011
Figure 54: Russia pharmaceuticals market value: $ billion, 2007–11
Figure 55: Russia pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 56: Russia pharmaceuticals market share: % share, by value, 2011
Figure 57: Russia pharmaceuticals market value forecast: $ billion, 2011–16
Figure 58: Forces driving competition in the pharmaceuticals market in Russia, 2011
Figure 59: Drivers of buyer power in the pharmaceuticals market in Russia, 2011
Figure 60: Drivers of supplier power in the pharmaceuticals market in Russia, 2011
Figure 61: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011
Figure 62: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011
Figure 63: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011
Figure 64: United Kingdom pharmaceuticals market value: $ billion, 2007–11
Figure 65: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 66: United Kingdom pharmaceuticals market share: % share, by value, 2011
Figure 67: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16
Figure 68: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011
Figure 69: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011
Figure 70: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011
Figure 71: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011
Figure 72: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011
Figure 73: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011
Figure 74: United States pharmaceuticals market value: $ billion, 2007–11
Figure 75: United States pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 76: United States pharmaceuticals market share: % share, by value, 2011
Figure 77: United States pharmaceuticals market value forecast: $ billion, 2011–16
Figure 78: Forces driving competition in the pharmaceuticals market in the United States, 2011
Figure 79: Drivers of buyer power in the pharmaceuticals market in the United States, 2011
Figure 80: Drivers of supplier power in the pharmaceuticals market in the United States, 2011
Figure 81: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011
Figure 82: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011
Figure 83: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011
Figure 84: Johnson & Johnson: revenues & profitability
Figure 85: Johnson & Johnson: assets & liabilities
Figure 86: Pfizer Inc.: revenues & profitability
Figure 87: Pfizer Inc.: assets & liabilities
Figure 88: AstraZeneca PLC: revenues & profitability
Figure 89: AstraZeneca PLC: assets & liabilities
Figure 90: GlaxoSmithKline Plc: revenues & profitability
Figure 91: GlaxoSmithKline Plc: assets & liabilities
Figure 92: Novartis AG: revenues & profitability
Figure 93: Novartis AG: assets & liabilities
Figure 94: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 95: Takeda Pharmaceutical Company Limited: assets & liabilities
Figure 96: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 97: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 98: Mitsubishi Tanabe Pharma Corporation: revenues & profitability
Figure 99: Mitsubishi Tanabe Pharma Corporation: assets & liabilities
Figure 100: Pharmstandard OJSC: revenues & profitability
Figure 101: Pharmstandard OJSC: assets & liabilities
Figure 102: Sanofi: revenues & profitability
Figure 103: Sanofi: assets & liabilities
Figure 104: Bayer AG: revenues & profitability
Figure 105: Bayer AG: assets & liabilities
Figure 106: Merck & Co., Inc.: revenues & profitability
Figure 107: Merck & Co., Inc.: assets & liabilities
